Proactive investorsLogo Proactive Investors UK Website

Search field
Additional information
Additional Information
Market: NASDAQ, NYSE EURONEXT
Sector: Pharmaceuticals
Epic: CRXL
News: Latest news
Web Site: Crucell
Other Articles:

RSS - Subscribe to the News Today on Proactive UK ▼

Monday March 15, 11:21Diamondcorp: a big cash injection and a lot of work to do

70% of the new money was raised from current shareholders, reflecting a hefty amount of faith in the management to deliver.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Sunday March 14, 05:46China's growth boosting commodity prices

With chunky economic numbers from China boosting commodity prices we take a brief look at the country's position in different market places - while noting also that hopes for a recovery in global trade appear to be borne out by freight rates.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Monday March 15, 09:01China's growth boosting commodity prices

The latest economic figures from China have put pressure on the dollar and boosted a number of high-yielding currencies, including the Australian dollar and the South African rand.

FULL ARTICLE ►
Crucell

Crucell

Crucell focuses on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide

Tuesday, February 09, 2010

Biopharmaceutical company Crucell N.V. reports record 2009 revenues and profits

company news image

Dutch biopharmaceutical company, Crucell N.V. (NASDAQ, NYSE Euronext: CRXL) reported that net profits in 2009 jumped 68% to €23.9 million as revenues climbed 26% to €358 million. Crucell is focused on research and development of vaccines, proteins and antibodies.

Strong revenue growth at the company was driven by a 59% increase in paediatric vaccine sales, and in spite of movements in the EUR/USD rate, which impacted the headline revenues figure by 3%. Crucell also reported good growth in endemic vaccines (18%), respiratory vaccines (12%) and other products (11%). Gross margins did however slip to 42% compared to 45% in 2008, though unfavourable currency movements and the timing of some milestone payments was the main culprit.

Operating profit for the full year soared to €39 million (FY 2008: €7.4 million) and net profit rose sharply to €23.9 million (FY 2008: €14.3 million). Net profit per share was €0.34 (FY 2008: €0.22). Cash and cash equivalents increased by €156.9 million to €327.8 million, thanks largely to a share placing with Johnson & Johnson (NYSE: JNJ) which was part of a wider strategic agreement for influenza antibody research.

"The key event of the year was the partnership agreement we signed with Johnson & Johnson (JNJ). This partnership, with a total deal value of over EUR1 billion, included a payment of over EUR300 million, mainly related to an equity investment of 18%. The partnership with JNJ provides us with additional R&D funding and enables us to further accelerate and expand our product development. In 2010 and onwards we have a responsibility to make the most of these opportunities," Crucell's Chief Executive Officer Ronald Brus said.

"Our world-class vaccine production plant in Seoul, Korea, is being constructed at record pace. This allows us to efficiently produce high volumes of vaccines in Asia. Our partner Adimmune has also successfully started production of influenza vaccines in Taiwan and is a promising future supplier of flu antigens for us."

Crucell’s Korean facility, in Yongin City, is expected to commence test runs in the second quarter of 2010.

AddThis Feed Button
Register here to be notified of future Crucell articles.

Investors interested in Crucell recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.